The 3.7% discordance rate, which corresponded to the 7.9% frequency of HER2+ CTCs, was reported by Ignatiadis et al. 17 in 101 patients with nonmetastatic breast cancer; CTCs were detected using the CellSearch® assay for HER2 immunofluorescence staining. This evidence concerns the gene ERBB2 and breast carcinoma.